UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN

HemaSphere, 2023-05, Vol.7 (S2), p.21-22

2023

Volltextzugriff (PDF)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE

HemaSphere, 2023-05, Vol.7 (S2), p.35-35

2023

Volltextzugriff (PDF)

P59 ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS‐COV‐2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID‐19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA

HemaSphere, 2023-05, Vol.7 (S2), p.43-43

2023

Volltextzugriff (PDF)

P60 EVOLVING OUTCOMES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: 20‐YEARS SINGLE CENTER EXPERIENCE

HemaSphere, 2023-05, Vol.7 (S2), p.43-44

2023

Volltextzugriff (PDF)

P01 LACTATE TRAFFICKING INHIBITION RESTORES SENSITIVITY TO PROTEASOME INHIBITHORS AND ORCHESTRATES IMMUNOMICROENVIRONMENT IN MULTIPLE MYELOMA

HemaSphere, 2023-05, Vol.7 (S2), p.9-9

2023

Volltextzugriff (PDF)

Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells

Hematological oncology, 2007-12, Vol.25 (4), p.164-169

2007

Volltextzugriff (PDF)

PB2279: REDUCED ABSOLUTE COUNT OF MONOCYTES IN PATIENTS CARRYING HEMATOLOGICAL NEOPLASMS AND SARS‐COV2 BREAKTHROUGH INFECTION

HemaSphere, 2022-06, Vol.6 (Suppl), p.2149-2150

2022

Volltextzugriff (PDF)

P02 ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS

HemaSphere, 2023-05, Vol.7 (S2), p.9-9

2023

Volltextzugriff (PDF)

Autonomic space and psychophysiological response

Psychophysiology, 1994-01, Vol.31 (1), p.44-61

1994

Volltextzugriff (PDF)

Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies

European journal of haematology, 2006-12, Vol.77 (6), p.480-485

2006

Volltextzugriff (PDF)

Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase

Leukemia research, 2009-06, Vol.33 (6), p.e17-e17

2009

Volltextzugriff (PDF)

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR–ABL kinase domain

Leukemia research, 2009-09, Vol.33 (9), p.e157-e158

2009

Volltextzugriff (PDF)

Serum levels of interleukin-16 in lymphoid malignancies

Leukemia & lymphoma, 2007-01, Vol.48 (6), p.1225-1227

2007

Volltextzugriff (PDF)

PB2189 FREE LIGHT CHAINS IN MULTIPLE MYELOMA: IS IT TIME TO EXTEND THEIR APPLICATION?

HemaSphere, 2019-06, Vol.3 (S1), p.982-n/a

2019

Volltextzugriff (PDF)

PS1318 LONG TERM FOLLOW‐UP OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS PRIMARY TREATED WITH DEXAMETHASONE, RITUXIMAB, AND CYCLOPHOSPHAMIDE: A SINGLE CENTRE EXPERIENCE

HemaSphere, 2019-06, Vol.3, p.602-n/a

2019

Volltextzugriff (PDF)

PS1318 LONG TERM FOLLOW‐UP OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS PRIMARY TREATED WITH DEXAMETHASONE, RITUXIMAB, AND CYCLOPHOSPHAMIDE: A SINGLE CENTRE EXPERIENCE

HemaSphere, 2019-06, Vol.3 (S1), p.602

2019

Volltextzugriff (PDF)

PF632 EARLY SALVAGE TREATMENT WITH SECOND‐GENERATION NOVEL AGENTS AT BIOCHEMICAL RELAPSE PROLONGS OVERALL SURVIVAL: A REAL‐WORLD SINGLE CENTER EXPERIENCE

HemaSphere, 2019-06, Vol.3 (S1), p.269-n/a

2019

Volltextzugriff (PDF)

PB2185 DARATUMUMAB MONOTHERAPY IN REAL LIFE COMMUNITY SETTING OF REFRACTORY MYELOMA PATIENTS: A RETROSPECTIVE UNICENTRIC STUDY

HemaSphere, 2019-06, Vol.3 (S1), p.980-n/a

2019

Volltextzugriff (PDF)

PS1362 TRYPTOPHAN DEPRIVATION DUE TO INCREASED IDO‐1 TRIGGERS A METABOLIC ADAPTIVE RESPONSE AND DOWN‐REGULATES CD38 IN MULTIPLE MYELOMA

HemaSphere, 2019-06, Vol.3 (S1), p.622-n/a

2019

Volltextzugriff (PDF)

PB2123 FEASIBILITY, TOLERABILITY AND EFFICACY OF CARFILZOMIB, LENALIDOMIDE AND DESAMETHASONE(KRD) IN RELAPSED REFRACTORY MYELOMA PATIENTS: A REAL‐LIFE SURVEY OF THE SICILIAN MYELOMA NETWORK

HemaSphere, 2019-06, Vol.3 (S1), p.956-n/a

2019

Volltextzugriff (PDF)

Letter to the Editor: Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase

Leukemia research, 2009-06, Vol.33 (6), p.e17-e17

2009

Volltextzugriff (PDF)

Vagal stimulation and cardiac chronotropy in rats

Journal of the autonomic nervous system, 1992-12, Vol.41 (3), p.221-226

1992

Volltextzugriff (PDF)

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain

Leukemia research, 2009, Vol.33 (9), p.e157-e158

2009

Volltextzugriff (PDF)

Are the fadings of R Coronae Borealis truly random?

The Astronomical journal, 1987-01, Vol.93, p.200-203

1987

Volltextzugriff (PDF)

Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort

Brazilian journal of medical and biological research, 2023-01, Vol.56 (1), p.e12488-e12488

2023

Volltextzugriff (PDF)

1 – 25 von 108

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE

P59 ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS‐COV‐2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID‐19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA

P60 EVOLVING OUTCOMES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: 20‐YEARS SINGLE CENTER EXPERIENCE

P01 LACTATE TRAFFICKING INHIBITION RESTORES SENSITIVITY TO PROTEASOME INHIBITHORS AND ORCHESTRATES IMMUNOMICROENVIRONMENT IN MULTIPLE MYELOMA

Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells

PB2279: REDUCED ABSOLUTE COUNT OF MONOCYTES IN PATIENTS CARRYING HEMATOLOGICAL NEOPLASMS AND SARS‐COV2 BREAKTHROUGH INFECTION

P02 ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS

Autonomic space and psychophysiological response

Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies

Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR–ABL kinase domain

Serum levels of interleukin-16 in lymphoid malignancies

PB2189 FREE LIGHT CHAINS IN MULTIPLE MYELOMA: IS IT TIME TO EXTEND THEIR APPLICATION?

PS1318 LONG TERM FOLLOW‐UP OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS PRIMARY TREATED WITH DEXAMETHASONE, RITUXIMAB, AND CYCLOPHOSPHAMIDE: A SINGLE CENTRE EXPERIENCE

PS1318 LONG TERM FOLLOW‐UP OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS PRIMARY TREATED WITH DEXAMETHASONE, RITUXIMAB, AND CYCLOPHOSPHAMIDE: A SINGLE CENTRE EXPERIENCE

PF632 EARLY SALVAGE TREATMENT WITH SECOND‐GENERATION NOVEL AGENTS AT BIOCHEMICAL RELAPSE PROLONGS OVERALL SURVIVAL: A REAL‐WORLD SINGLE CENTER EXPERIENCE

PB2185 DARATUMUMAB MONOTHERAPY IN REAL LIFE COMMUNITY SETTING OF REFRACTORY MYELOMA PATIENTS: A RETROSPECTIVE UNICENTRIC STUDY

PS1362 TRYPTOPHAN DEPRIVATION DUE TO INCREASED IDO‐1 TRIGGERS A METABOLIC ADAPTIVE RESPONSE AND DOWN‐REGULATES CD38 IN MULTIPLE MYELOMA

PB2123 FEASIBILITY, TOLERABILITY AND EFFICACY OF CARFILZOMIB, LENALIDOMIDE AND DESAMETHASONE(KRD) IN RELAPSED REFRACTORY MYELOMA PATIENTS: A REAL‐LIFE SURVEY OF THE SICILIAN MYELOMA NETWORK

Letter to the Editor: Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase

Vagal stimulation and cardiac chronotropy in rats

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain

Are the fadings of R Coronae Borealis truly random?

Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort

Suchergebnisse filtern